Summit Therapeutics (SMMT) has seen a remarkable rise, gaining over 15% as it transitions from a small-cap to a large-cap biotech, largely due to its cancer drug ivonescimab, which is already approved in China. The company recently submitted an application to the FDA for ivonescimab’s use in treating EGFR-mutated non-small cell lung cancer. However, the FDA has indicated that a statistically significant improvement in overall survival is crucial for approval, putting the stock at risk of a significant decline if the application is rejected by the November 14 deadline.

In contrast, smaller biotechs like Axsome Therapeutics (AXSM) and Madrigal Pharmaceuticals (MDGL) are making strides that could overshadow Summit. Axsome is poised for potential growth with its revenue-generating drugs and upcoming FDA decisions on new indications, while Madrigal’s sales from its FDA-approved treatment for metabolic dysfunction are skyrocketing. Both companies are positioned to capitalize on their respective markets, enhancing their valuations.

Investors should weigh the high-risk, high-reward nature of these biotech stocks. While Summit may face immediate challenges, its long-term potential in oncology could make it an attractive option for those willing to navigate the volatility of the sector.

Source: fool.com